Proteomics and systems biology for understanding diabetic nephropathy

Jonathan Starkey, Ronald Tilton

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Like many diseases, diabetic nephropathy is defined in a histopathological context and studied using reductionist approaches that attempt to ameliorate structural changes. Novel technologies in mass spectrometry-based proteomics have the ability to provide a deeper understanding of the disease beyond classical histopathology, redefine the characteristics of the disease state, and identify novel approaches to reduce renal failure. The goal is to translate these new definitions into improved patient outcomes through diagnostic, prognostic, and therapeutic tools. Here, we review progress made in studying the proteomics of diabetic nephropathy and provide an introduction to the informatics tools used in the analysis of systems biology data, while pointing out statistical issues for consideration. Novel bioinformatics methods may increase biomarker identification, and other tools, including selective reaction monitoring, may hasten clinical validation.

Original languageEnglish (US)
Pages (from-to)479-490
Number of pages12
JournalJournal of Cardiovascular Translational Research
Volume5
Issue number4
DOIs
StatePublished - Aug 2012

Fingerprint

Systems Biology
Diabetic Nephropathies
Proteomics
Informatics
Systems Analysis
Computational Biology
Renal Insufficiency
Mass Spectrometry
Biomarkers
Technology
Therapeutics

Keywords

  • Bioinformatics
  • Diabetes
  • Diabetic nephropathy
  • Mass spectrometry
  • Proteomics
  • Sytems biology

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Genetics
  • Genetics(clinical)
  • Molecular Medicine
  • Pharmaceutical Science

Cite this

Proteomics and systems biology for understanding diabetic nephropathy. / Starkey, Jonathan; Tilton, Ronald.

In: Journal of Cardiovascular Translational Research, Vol. 5, No. 4, 08.2012, p. 479-490.

Research output: Contribution to journalArticle

@article{026002d2a2734efca75c95a7436bd8bc,
title = "Proteomics and systems biology for understanding diabetic nephropathy",
abstract = "Like many diseases, diabetic nephropathy is defined in a histopathological context and studied using reductionist approaches that attempt to ameliorate structural changes. Novel technologies in mass spectrometry-based proteomics have the ability to provide a deeper understanding of the disease beyond classical histopathology, redefine the characteristics of the disease state, and identify novel approaches to reduce renal failure. The goal is to translate these new definitions into improved patient outcomes through diagnostic, prognostic, and therapeutic tools. Here, we review progress made in studying the proteomics of diabetic nephropathy and provide an introduction to the informatics tools used in the analysis of systems biology data, while pointing out statistical issues for consideration. Novel bioinformatics methods may increase biomarker identification, and other tools, including selective reaction monitoring, may hasten clinical validation.",
keywords = "Bioinformatics, Diabetes, Diabetic nephropathy, Mass spectrometry, Proteomics, Sytems biology",
author = "Jonathan Starkey and Ronald Tilton",
year = "2012",
month = "8",
doi = "10.1007/s12265-012-9372-9",
language = "English (US)",
volume = "5",
pages = "479--490",
journal = "Journal of Cardiovascular Translational Research",
issn = "1937-5387",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Proteomics and systems biology for understanding diabetic nephropathy

AU - Starkey, Jonathan

AU - Tilton, Ronald

PY - 2012/8

Y1 - 2012/8

N2 - Like many diseases, diabetic nephropathy is defined in a histopathological context and studied using reductionist approaches that attempt to ameliorate structural changes. Novel technologies in mass spectrometry-based proteomics have the ability to provide a deeper understanding of the disease beyond classical histopathology, redefine the characteristics of the disease state, and identify novel approaches to reduce renal failure. The goal is to translate these new definitions into improved patient outcomes through diagnostic, prognostic, and therapeutic tools. Here, we review progress made in studying the proteomics of diabetic nephropathy and provide an introduction to the informatics tools used in the analysis of systems biology data, while pointing out statistical issues for consideration. Novel bioinformatics methods may increase biomarker identification, and other tools, including selective reaction monitoring, may hasten clinical validation.

AB - Like many diseases, diabetic nephropathy is defined in a histopathological context and studied using reductionist approaches that attempt to ameliorate structural changes. Novel technologies in mass spectrometry-based proteomics have the ability to provide a deeper understanding of the disease beyond classical histopathology, redefine the characteristics of the disease state, and identify novel approaches to reduce renal failure. The goal is to translate these new definitions into improved patient outcomes through diagnostic, prognostic, and therapeutic tools. Here, we review progress made in studying the proteomics of diabetic nephropathy and provide an introduction to the informatics tools used in the analysis of systems biology data, while pointing out statistical issues for consideration. Novel bioinformatics methods may increase biomarker identification, and other tools, including selective reaction monitoring, may hasten clinical validation.

KW - Bioinformatics

KW - Diabetes

KW - Diabetic nephropathy

KW - Mass spectrometry

KW - Proteomics

KW - Sytems biology

UR - http://www.scopus.com/inward/record.url?scp=84866062801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866062801&partnerID=8YFLogxK

U2 - 10.1007/s12265-012-9372-9

DO - 10.1007/s12265-012-9372-9

M3 - Article

VL - 5

SP - 479

EP - 490

JO - Journal of Cardiovascular Translational Research

JF - Journal of Cardiovascular Translational Research

SN - 1937-5387

IS - 4

ER -